Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Revaccination with Adacel 4–5 Years After Previous Dose
2015-005590-20Phase 4
- Sponsor
- Sanofi
- Start
- Jan 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of acellular pertussis vaccine in Tetanus, diphtheria and pertussis, sponsored by Sanofi. Primary endpoint: Solicited local and systemic reactions within 14 days.
02
Drugs
acellular pertussis vaccine
03
Conditions
Tetanusdiphtheriapertussis
Beyond the preview
Go deeper on 2015-005590-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005590-20.